These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 30907986)

  • 1. Nimotuzumab inhibits epithelial-mesenchymal transition in prostate cancer by targeting the Akt/YB-1/AR axis.
    Hu S; Duan YX; Zhou Q; Wang Y; Lu Q
    IUBMB Life; 2019 Jul; 71(7):928-941. PubMed ID: 30907986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. YB-1 expression promotes epithelial-to-mesenchymal transition in prostate cancer that is inhibited by a small molecule fisetin.
    Khan MI; Adhami VM; Lall RK; Sechi M; Joshi DC; Haidar OM; Syed DN; Siddiqui IA; Chiu SY; Mukhtar H
    Oncotarget; 2014 May; 5(9):2462-74. PubMed ID: 24770864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Y-box binding protein 1 (YB-1) promotes gefitinib resistance in lung adenocarcinoma cells by activating AKT signaling and epithelial-mesenchymal transition through targeting major vault protein (MVP).
    Lou L; Wang J; Lv F; Wang G; Li Y; Xing L; Shen H; Zhang X
    Cell Oncol (Dordr); 2021 Feb; 44(1):109-133. PubMed ID: 32894437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen receptor as a regulator of ZEB2 expression and its implications in epithelial-to-mesenchymal transition in prostate cancer.
    Jacob S; Nayak S; Fernandes G; Barai RS; Menon S; Chaudhari UK; Kholkute SD; Sachdeva G
    Endocr Relat Cancer; 2014 Jun; 21(3):473-86. PubMed ID: 24812058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression.
    Shiota M; Takeuchi A; Song Y; Yokomizo A; Kashiwagi E; Uchiumi T; Kuroiwa K; Tatsugami K; Fujimoto N; Oda Y; Naito S
    Endocr Relat Cancer; 2011 Aug; 18(4):505-17. PubMed ID: 21652770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resveratrol inhibits DHT-induced progression of prostate cancer cell line through interfering with the AR and CXCR4 pathway.
    Jang YG; Go RE; Hwang KA; Choi KC
    J Steroid Biochem Mol Biol; 2019 Sep; 192():105406. PubMed ID: 31185279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sin1 promotes proliferation and invasion of prostate cancer cells by modulating mTORC2-AKT and AR signaling cascades.
    Huang Y; Feng G; Cai J; Peng Q; Yang Z; Yan C; Yang L; Wang Z
    Life Sci; 2020 May; 248():117449. PubMed ID: 32088212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breviscapine suppresses the growth and metastasis of prostate cancer through regulating PAQR4-mediated PI3K/Akt pathway.
    Ye J; Gao M; Guo X; Zhang H; Jiang F
    Biomed Pharmacother; 2020 Jul; 127():110223. PubMed ID: 32413672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long non-coding DANCR targets miR-185-5p to upregulate LIM and SH3 protein 1 promoting prostate cancer via the FAK/PI3K/AKT/GSK3β/snail pathway.
    Sun W; Zu S; Shao G; Wang W; Gong F
    J Gene Med; 2021 Jul; 23(7):e3344. PubMed ID: 33885171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
    Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
    Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hsa_circ_0030586 promotes epithelial-mesenchymal transition in prostate cancer via PI3K-AKT signaling.
    Luo GC; Chen L; Fang J; Yan ZJ
    Bioengineered; 2021 Dec; 12(2):11089-11107. PubMed ID: 34852706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Periostin Mediates TGF-β-Induced Epithelial Mesenchymal Transition in Prostate Cancer Cells.
    Hu Q; Tong S; Zhao X; Ding W; Gou Y; Xu K; Sun C; Xia G
    Cell Physiol Biochem; 2015; 36(2):799-809. PubMed ID: 26021267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upregulation of long non-coding RNA PlncRNA-1 promotes proliferation and induces epithelial-mesenchymal transition in prostate cancer.
    Jin Y; Cui Z; Li X; Jin X; Peng J
    Oncotarget; 2017 Apr; 8(16):26090-26099. PubMed ID: 28212533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Difference in protein expression profile and chemotherapy drugs response of different progression stages of LNCaP sublines and other human prostate cancer cells.
    Lin HP; Lin CY; Hsiao PH; Wang HD; Jiang SS; Hsu JM; Jim WT; Chen M; Kung HJ; Chuu CP
    PLoS One; 2013; 8(12):e82625. PubMed ID: 24349321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of SPDEF and gain of TGFBI activity after androgen deprivation therapy promote EMT and bone metastasis of prostate cancer.
    Chen WY; Tsai YC; Yeh HL; Suau F; Jiang KC; Shao AN; Huang J; Liu YN
    Sci Signal; 2017 Aug; 10(492):. PubMed ID: 28811384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The miRNAs 203a/210-3p/5001-5p regulate the androgen/androgen receptor/YAP-induced migration in prostate cancer cells.
    Huo C; Kuo YY; Lin CY; Shiah SG; Li CY; Huang SP; Chen JK; Wang WC; Kung HJ; Chuu CP
    Cancer Med; 2024 Aug; 13(16):e70106. PubMed ID: 39149855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NDRG2 suppresses proliferation, migration, invasion and epithelial-mesenchymal transition of esophageal cancer cells through regulating the AKT/XIAP signaling pathway.
    Yang CL; Zheng XL; Ye K; Ge H; Sun YN; Lu YF; Fan QX
    Int J Biochem Cell Biol; 2018 Jun; 99():43-51. PubMed ID: 29530788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis.
    Lu C; Shan Z; Hong J; Yang L
    Int J Oncol; 2017 Jul; 51(1):235-244. PubMed ID: 28534966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo.
    Wang M; Liu X; Guo J; Weng X; Jiang G; Wang Z; He L
    Biochem Biophys Res Commun; 2015 Nov; 467(2):310-5. PubMed ID: 26435505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoisoliquiritin exerts tumor suppressive effects on prostate cancer by repressing androgen receptor activity.
    Chen C; Shao R; Li B; Zhai Y; Wang T; Li X; Miao L; Huang J; Liu R; Liu E; Zhu Y; Gao X; Zhang H; Wang Y
    Phytomedicine; 2021 May; 85():153514. PubMed ID: 33676083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.